Blue blocking IOLs are not the best option

Article

Ultraviolet (UV) and violet blocking intraocular lenses (IOLs) can provide protection from radiation and offer good quality of vision, however, blocking blue light can actually cause a loss in quality of vision.

Ultraviolet (UV) and violet blocking intraocular lenses (IOLs) can provide protection from radiation and offer good quality of vision, however, blocking blue light can actually cause a loss in quality of vision, according to Alessandro Franchini and Eleonora Vaccari from the University of Florence, Italy.

The study, which aimed to compare three different IOL filters, was conducted using a dedicated software and a pseudophakic eye model. The eye CIE day and night curves were computed through three different filters: the first blocks UV wavelights from 300 to 400 nm, the second blocks UV and violet (400 to 440 nm) wavelights (UVV) and the third blocks UV, violet and 50% of blue light at 450 nm and 25% at 480 nm (UVVB).

The investigators found that there were negligible differences between the three filters in day curves. In scotopic conditions, the UV filter guaranteed an integral of efficiency of 23.7 (100%), the UVV filter of 23.31 (97%) and the UVVB of 21.49 (90%).

According to Dr Franchini and Dr Vaccari, there is no proof that blocking blue light can guarantee further retinal protection and, given that it can actually cause a reduction in quality of vision, the authors conclude that UV and violet light blocking IOLs offer the best solution.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.